Market Research Report
Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022
|Published by||GlobalData||Product code||232350|
|Published||Content info||46 Pages
|Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022|
|Published: July 31, 2013||Content info: 46 Pages||
This publication has been discontinued on February 2, 2017.
GlobalData has released its new report, "Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.
Lyxumia (lixisenatide) is a fourth-to-market GLP-1 receptor agonist developed by Zealand Pharma and in-licensed to Sanofi. It was approved in the EU in February 2013, and is under review as a New Drug Application (NDA) by the FDA as of July 2013.